Entropy Neurodynamics (ASX:ENP) has taken another step forward in its clinical exploration of psychedelic-assisted therapy, announcing that the third patient in its trial of TRP-8803 has completed dosing and achieved what the company describes as a full and controlled psychedelic response.
The Melbourne-based company is investigating an intravenous formulation of psilocin for the treatment of Binge Eating Disorder, a condition affecting millions globally and often resistant to existing therapies. The third participant received two infusions, spaced two weeks apart, in late March and early April 2026. According to the company, clinicians were able to replicate the onset, depth and duration of the psychedelic experience with precision, a key objective of the trial and a distinguishing feature of the intravenous approach.
The study is designed to enrol 12 patients split across two cohorts, each receiving two doses of TRP-8803 alongside supportive therapy. The first cohort is nearing completion, with several patients already progressing through dosing and follow-up stages, while a second cohort is being prepared using insights from the initial group.
Early signals from the trial have been encouraging, the company said. The first patient, who has completed post-treatment assessment, demonstrated improvements across multiple domains, including reductions in binge eating behaviour, anxiety and depression, as well as gains in emotional regulation and overall well-being. The company reports that all patients treated so far have experienced a psychedelic response, reinforcing confidence in the drug’s consistency.
By delivering psilocin directly into the bloodstream, TRP-8803 aims to eliminate inconsistencies in metabolism and absorption, allowing clinicians to better manage the therapeutic experience. This level of control is considered essential for scaling psychedelic-assisted treatments in real-world clinical settings.
Entropy’s chief executive officer, Jason Carroll, said, “Completion of dosing for our second and third patients highlight continued, disciplined progress across the TRP-8803 clinical program and reinforces our ability to deliver consistent and controlled psychedelic experiences using our IV-infused psilocin platform. Achieving a full psychedelic response in a real clinical setting, demonstrates that TRP-8803 can deliver precise onset, depth and duration required for a scalable therapeutic model – something oral psilocybin has not been able to achieve."